In the present study, the resistance mechanisms against carbapenems and aminoglycosides for 23 strains of multi-drug-resistant Acinetobacter baumannii isolated at a university hospital were investigated. Methods: The minimal inhibitory concentrations (MICs) were determined via broth microdilution or Etest. The genes encoding OXA-type carbapenemases and 16S rRNA methylase were identified using multiplex PCR, and the amplified products were sequenced. Conjugation experiments were conducted, and an epidemiologic study was performed using enterobacterial repetitive intergenic consensus (ERIC)-PCR. Results: In the isolates, the MICs of the tested aminoglycosides, including arbekacin, were ＞1024 μg/ mL; the MICs of aztreonam, cefepime, ceftazidime, and ciprofloxacin ranged from 64 to 128 μg/mL; and the MICs of carbapenem ranged from 32 to 64 μg/ mL, as determined through the broth microdilution test. According to the E-test, the MICs of ampicillin/ sulbactam and colistin were 8 and 0.25 to 0.38 μg/ mL, respectively. Sequence analysis confirmed that all of the isolates expressed carbapenemases OXA-23 and OXA-66, as well as armA 16S rRNA methylase. In addition, ISAba1 was identified upstream of the gene encoding OXA-23. OXA-23 and armA were not transferred to Escherichia coli J53 cells in the transconjugation experiments. ERIC-PCR molecular fingerprinting produced a single pattern in all cases.
INTRODUCTION
Infections caused by multi-drug resistant Acinetobacter baumannii (MDRAB) have been reported in many countries [1, 2] .
These infections are most common in intensive care units (ICUs), where they occur mainly in conjunction with ventilator-associated pneumonia, urinary tract infections, or bacteremia. Carbapenem-resistant Acinetobacter spp. are increasing due to the emergence of carbapenem-hydrolyzing β-lactamases belonging to molecular classes B and D [3, 4] . Whereas class B carbapenemase, metallo-β-lactamase (MBL), have been frequently founded in non-baumannii members of this genus, an increase in class D carbapenemases has been reported in A. baumannii in South Korea [4, 5] . The OXA-type class D carbapenemases of A. baumannii can be divided into the following subgroups: OXA-23, -24, -51, and -58. Of these, OXA-23 and -51 are the most common and frequently occur simultaneously in a single isolate; however, OXA-23 is acquired enzyme that frequently leads to an outbreak at ICUs around the world [4, 6, 7] , whereas OXA-51 is an intrinsic enzyme. Recently, a 16S rRNA methylase that confers high-level resistance to 4,6-substituted deoxystreptamines, including arbekacin, amikacin, tobramycin, and gentamicin, through the methylation of 16S rRNA leading to a loss of affinity for aminoglycosides was identified in vari- GTG ATA ARA TGG CBG GTC GT  CGB GCR TGC ATY TTG TCR T  GAT CGG ATT GGA GAA CCA GA  ATT TCT GAC CGC ATT TCC AT  GGT TAG TTG GCC CCC TTA AA  AGT TGA GCG AAA AGG GGA TT  TAA TGC TTT GAT CGG CCT TG  TGG ATT GCA CTT CAT CTT GG  AAG TAT TGG GGC TTG TGC TG  CCC CTC TGC GCT CTA CAT AC  CAC GAA TGC AGA AGT TG  ATT TCT GAC CGC ATT TCC AT  TGG ATT GCA CTT CAT CTT GG  CAT GGT TTG GTG GTT CTT GT  ATA ATT TGG CGG ACT TTG GC  ATG TTC AAA CTT TTG AGT AAG  CTA CTC AAC GAC TGA GCG  TAC AAG GGA TTC GGC ATCG  TAA TGG CCT GTT CCC ATG TG  CAA ATG GAT AAG AAT GAT GTT  TTA TTT CTG AAA TCC ACT  ATG AAC ATC AAC GAT GCC CT  CCT TCT GAT TGG CTT ATC ous Gram-negative bacilli, including Acinetobacter spp., Pseudomonas spp., and various Enterobacteriaceae [8, 9] . Additionally, the dissemination of various 16S rRNA methylase genes, including armA, rtmB, and rtmA, has been reported in Japan [10] , Europe [11] , North America [12] , Brazil [13] , Taiwan [14] , and South Korea [9] . Carbapenems and aminoglycosides can produce a synergistic effect and thus are often used together to treat MDRAB infections [15] . Therefore, strains bearing resistance to both carbapenems and aminoglycosides would have considerable clinical impact.
Twenty-three strains of MDRAB were isolated from an ICU and a few wards of a university hospital in South Korea, over a 5-month period in 2007. The strains were resistant to all of the β-lactam drugs tested, and they yielded a positive modified Hodge test result, but a negative MBL disk test result. In addition, the strains did not produce an inhibitory zone around a Kirby-Bauer disk impregnated with 30μg of arbekacin, suggesting the production of 16S rRNA methylase.
Here, we investigated the mechanism of resistance to carbapenems and aminoglycosides in the isolates, using phenotypic and molecular methods in addition to molecular epidemiologic experiments.
MATERIALS AND METHODS

Bacterial strains identification, antimicrobial susceptibility testing and carbapenemase screening
The bacterial strains identification was firstly carried out by the Vitek system with a GNI＋ card (bioMérieux, Hazelwood, MO, USA), and subsequently were confirmed by determination of the partial rpoB gene sequence [16] .
The minimal inhibitory concentrations (MICs) of imipenem (Merk & Co., Inc., Elkton, MD, USA), meropenem (Yuhanyanghang Co, Seoul, Korea), ceftazidime (CJ Jeiljedang Co, Seoul, Korea), cefepime (Boryung Pharmaceutical, Seoul, Korea), arbekacin (Joongwae Phamaceutical Co., Seoul, Korea), amikacin (Boryung Pharmaceutical Co., Seoul, Korea), gentamicin (Dongshin Pharmaceutical, Seoul, Korea), tobramycin (Daewoong Pharmaceutical Co, Seoul, Korea), and ciprofloxacin (Bayer Korea Co, Seoul, Korea) were determined for the isolates by the CLSI broth microdilution method [17] . The MICs of ampicillin/sulbactam, piperacillin/tazobactam, and colistin were determined by Etest (AB BIODISK, Solna, Sweden). Pseudomonas aeruginosa ATCC 27853 was used as a reference strain.
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PCR and sequencing
The amplification of blaIMP-1, blaVIM-2, and blaSIM-1 was done as described previously [20] [21] [22] . Screening for OXA-type carbapenemases in the isolates was carried out using a multiplex PCR assay with the primers and reaction conditions described by Woodford et al. [23] . ISAba1 was amplified using the primers ISAba1/OXA-23 and ISAba1/OXA-51 like [24] . The amplification of armA and rtmB was conducted by duplex PCR for 16S rRNA methylase using previously described primers [8, 14] . For each reaction, a fresh bacterial colony was suspended in 500μL of sterile distilled water and boiled at 100 o C for 10 min. After centrifugation, 2μL of the supernatant were used for PCR with the primers described in Table 1 . Amplification of the template DNA was performed using a GeneAmp 9700 PCR system (Applied Biosystems, Foster City, CA, USA). The reaction con-
For eight arbitrarily selected isolates, the amplified products were purified using a QIAquick PCR purification kit (Qiagen, Inc., Chatsworth, CA, USA) and sequenced on both strands using an ABI PRISM 3100 genetic analyzer (Applied Biosystems). The sequences were compared with those in the GenBank nucleotide database (www. ncbi.nlm.nih.gov/blast/).
Transconjugation
Conjugation experiments were conducted by broth mating, using Escherichia coli J53 as the recipient [25] . Transconjugants were selected on MacConkey agar supplemented with 100μg/ mL sodium azide and 2μg/mL ceftazidime (for blaOXA-23) or 30 μg/mL amikacin (for armA 16S rRNA methylase).
Enterobacterial repetitive intergenic consensus (ERIC)-PCR typing
DNA fingerprinting was performed by ERIC-PCR using the primers ERIC1R and ERIC2 with genomic DNA as the template, as described previously [26] 
*blaOXA-23 like and blaOXA-51 like was positive by multiplex PCR, and the amplified products were respectively confirmed to OXA-23 and OXA-66 type by sequencing analysis in eight isolates selected arbitrarily. † ISAb1 was located to upstream of blaOXA-23 (separated to 27 bp) but was not presented at upstream of blaOXA-66. ‡ The amplified products were confirmed to be armA gene by the sequencing analysis. Abbreviations: ICU, intensive care unit; W, ward; F, fluid; BA, bronchial aspirate. 
RESULTS
Bacterial strains identification and characterization
All of the isolates were identified as A. baumannii using a Vitek 2 system and rpoB gene sequencing. The isolates exhibited resistance to all of the antimicrobial agents tested, including imipenem and meropenem (except colistin and ampicillin/sulbactam), and they showed high-level resistance (＞ 1,024μg/mL) to aminoglycosides, including amikacin, gentamicin, tobramycin, and arbekacin (Table 2) . Positive results were obtained using a modified Hodge test, and negative results were obtained with MBL disk tests, suggesting the production of carbapenemase, rather than MBLs. In addition, the lack of a zone of inhibition for arbekacin suggests the existence of 16S rRNA methylase.
Detection of OXA-type carbapenemase and 16S ribosomal RNA genes
None of the isolates produced products for blaIMP-1, blaVIM-2, or blaSIM-1. All of the isolates harbored blaOXA-23-and blaOXA-51-like carbapenemase genes, and the amplified products from eight arbitrarily selected isolates were confirmed to be blaOXA-23 and blaOXA-66 by sequence analysis. Furthermore, ISAba1 was positively identified by ISAba1/OXA-23 PCR and was located 27 bp upstream of blaOXA-23 based on sequence analysis. In addition, the isolates were found to possess armA, a 16S rRNA methylase gene, by PCR and sequencing (Table 3) .
Transconjugation and strain typing
The genes encoding OXA-23 carbapenemase and armA 16S rRNA methylase were not transferred to E. coli J53 cells in repeated transconjugation experiments. Moreover, the isolates exhibited single DNA fingerprinting patterns by ERIC-PCR (Fig. 1) .
DISCUSSION
Carbapenems are stable against most β-lactamases and are often used as a last resort to treat cases of MDRAB. However, since OXA-23 carbapenemase was first described from A. baumannii detected in Scotland in 1985 [27] , the global incidence of OXA-23 carbapenemase-producing A. baumannii has increased, creating difficulty in treating infected patients, especially those admitted to ICUs [6, 28] . Aminoglycoside antibiotics are frequently ineffective against strains of A. baumannii, but are nevertheless used together with carbapenems to treat infected patients because the two agents have a synergistic effect [15] . The incidence of infection by A. baumannii with armA 16S rRNA methylase has increased, leading to reports of highlevel resistance to most aminoglycosides [29] . Moreover, North American [12] , Chinese [30, 31] , and South Korean [32] reports have documented the co-production of blaOXA-23 and armA, which can pose therapeutic challenges.
During a 5-month period in 2007, 23 strains of imipenem-resistant A. baumannii were isolated from a university hospital, beginning with an isolate obtained from a patient in an ICU. All of the isolates co-expressed blaOXA-23 and armA 16S rRNA methylase and showed pan-drug resistance, except to colistin and ampicillin/sulbactam. Moreover, the isolates showed a single DNA fingerprinting pattern by ERIC-PCR, suggesting an outbreak caused by single clonal isolates. Six of the 23 isolates might have caused the infection and the other 17 patients had colonized forms of these isolates. Interestingly, five of the 17 colonized isolates were obtained from bronchial aspirates, suggesting that contaminated bronchoscopy equipment was the source of infection.
The isolates had blaOXA-66 in addition to blaOXA-23, as reported previously in China [31] . The isolates also possessed ISAba1 upstream of blaOXA-23, which plays an important role in resistance to carbapenems, including imipenem. There was a 27-bp sequence between ISAba1 and blaOXA-23, which was identical to ARI-1 [27] . At upstream of blaOXA-66, ISAba1 was not amplified by ISAba1/OXA-51-like PCR. Phenotypic and genetic analyses for MBLs produced negative results for all of the isolates. Therefore, the resistance to imipenem and meropenem (MIC, 32 ∼64μg/mL) may be caused by the presence of carbapenemases OXA-23 (mainly) and -66.
On the one other hand, no zone of inhibition was produced with any of the tested aminoglycoside antibiotic disks, including disks with amikacin, gentamicin, tobramycin, and arbekacin, suggesting the production of 16S rRNA methylase. Among the known 16S rRNA methylases, armA was identified in all of the isolates, which is similar to isolates of A. baumannii in Korea [9] . Consequently, the multidrug resistance of A. baumannii strains in this study may be attributable to the co-production of carbapenemase OXA-23 and armA 16S rRNA methylase. Interestingly, the isolates in this study were similar to those that caused an outbreak of A. baumannii infections, as described by Kim et al. [32] , in that they simultaneously carried blaOXA-23, blaOXA-51, blaPER-1, and armA. The isolates also showed similar antibiotic resistance patterns, except for ampicillin-sulbactam (＞32μg/mL), which might have been caused by the acquisition of blaPER-1. In addition, the infections occurred during the same time period, i.e., May to October 2007 in this study and May to July 2007 in Gyungnam province [32] , in different regions with interrelated life zones, suggesting the dissemination in South Korea of A. baumannii isolates co-producing OXA-type carbapenemases and 16S rRNA methylase.
In conclusion, infections of MDRAB co-producing OXA-23 carbapenemase and armA 16S rRNA methylase occurred in a university hospital in South Korea. The resistance mechanism identified in this study could threaten existing therapeutic modalities for such infections. Stricter surveillance and more rapid detection are essential to reduce the spread of MDRAB, including OXA-type carbapenemases and 16S rRNA methylase co-producing microorganism.
